Liminatus Pharma Amends Merger Agreement with InnocsAI
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Source: Newsfilter
- Merger Agreement Restructured: Liminatus Pharma has amended its merger agreement with InnocsAI to allow closing before stockholder approval, expected on July 2, 2026, demonstrating the company's commitment to rapid strategic integration.
- Significant Transaction Value: The total implied value of the transaction is approximately $320 million, with InnocsAI equity holders receiving a mix of Liminatus common stock and newly designated non-voting convertible preferred stock, indicating flexibility and innovation in the company's capital structure.
- Strategic Integration Opportunities: Post-merger, Liminatus will expand its oncology pipeline by integrating cell therapy and immunotherapy, which is expected to yield multiple preclinical product candidates and enhance future market competitiveness.
- Shareholder Value Enhancement: The merger is poised to create long-term shareholder value, particularly as the diversified oncology platform is likely to attract more strategic partnerships and licensing opportunities, further solidifying its market position.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LIMN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LIMN
About LIMN
Liminatus Pharma, Inc. is a pre-clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies. The Company is engaged in the development of a second generation CD47 blockade antibody designed to prevent the induction of severe anemia and thrombocytopenia observed with first generation CD47 blockades. The Company’s candidate, IBA101, is a humanized anti-CD47 monoclonal antibody. The CD47 checkpoint inhibitor’s initial indication is expected to be patients with advanced solid cancers, including non-small cell lung cancer. IBA101 is a humanized anti-human CD47 monoclonal antibody with a human IgG4 Fc, designed to preferentially bind nucleated cells, such as immune and tumor cells, while sparing anucleate cells like red blood cells and platelets. IBA101 promotes macrophage-mediated phagocytosis of tumor cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Liminatus Pharma Amends Merger Agreement with InnocsAI
- Merger Agreement Restructuring: Liminatus Pharma has amended its merger agreement with InnocsAI, allowing the transaction to close before obtaining stockholder approval, now expected on July 2, 2026, demonstrating the company's commitment to rapid strategic integration.
- Transaction Terms Details: Under the amended terms, InnocsAI equity holders will receive a mix of Liminatus common stock and newly designated non-voting convertible preferred stock, with an implied transaction value of approximately $320 million, reflecting confidence in future growth prospects.
- Equity Structure Arrangement: InnocsAI holders will receive up to 19.99% of Liminatus common shares, with the remainder in non-voting convertible preferred stock that can only convert to common shares upon stockholder approval, adhering to Nasdaq regulations.
- Strategic Significance: Liminatus CEO Chris Kim stated that this merger represents a pivotal step in the company's strategy to diversify its oncology biotech portfolio, as InnocsAI's cell therapy platform complements Liminatus' immuno-oncology programs, creating multiple opportunities for long-term shareholder value.
See More
Liminatus Pharma Amends Merger Agreement with InnocsAI
- Merger Agreement Restructured: Liminatus Pharma has amended its merger agreement with InnocsAI to allow closing before stockholder approval, expected on July 2, 2026, demonstrating the company's commitment to rapid strategic integration.
- Significant Transaction Value: The total implied value of the transaction is approximately $320 million, with InnocsAI equity holders receiving a mix of Liminatus common stock and newly designated non-voting convertible preferred stock, indicating flexibility and innovation in the company's capital structure.
- Strategic Integration Opportunities: Post-merger, Liminatus will expand its oncology pipeline by integrating cell therapy and immunotherapy, which is expected to yield multiple preclinical product candidates and enhance future market competitiveness.
- Shareholder Value Enhancement: The merger is poised to create long-term shareholder value, particularly as the diversified oncology platform is likely to attract more strategic partnerships and licensing opportunities, further solidifying its market position.
See More
Liminatus Pharma Enters Warrant Exercise Agreement
- Financing Agreement: Liminatus Pharma has signed a warrant exercise agreement with existing accredited investors to exercise a total of 10.34 million warrants, expected to generate $1.9 million in cash flow, enhancing its financial flexibility to support R&D initiatives.
- New Warrant Issuance: Concurrently with the exercise of existing warrants, holders were issued new unregistered warrants for a total of 20.688 million shares at an exercise price of $0.18 per share, indicating the company's confidence in future shareholder approval.
- Stock Price Volatility: LIMN's stock has traded between $0.13 and $33.66 over the past year, closing at $0.15 on Wednesday, down 22.21%, reflecting market caution regarding the company's short-term outlook.
- Market Reaction: In pre-market trading, LIMN shares rose 0.20% to $0.15, and despite the overall weak performance, the market's response to the new financing agreement shows a degree of optimism.
See More
Liminatus Pharma Enters Warrant Exercise Agreement
- Financing Progress: Liminatus Pharma has entered into a warrant exercise agreement, expected to generate $1.9 million in gross proceeds, enhancing the company's liquidity to support future R&D initiatives.
- Share Issuance: The agreement involves the exercise of 10.34 million shares of common stock warrants while issuing 20.68 million new unregistered warrants, which may dilute existing shareholders' equity but provides additional capital support for the company.
- Market Reaction: The market reacted positively to the agreement, with investors expressing optimism about the company's future growth potential, which could drive the stock price up in the short term and bolster market confidence.
- Strategic Implications: This financing allows Liminatus Pharma to accelerate its R&D projects, particularly in new drug development, aiming to enhance its competitiveness and market position in the biopharmaceutical industry.
See More
Liminatus Pharma Enters Warrant Exercise Agreement for $1.9 Million
- Warrant Exercise Agreement: Liminatus Pharma has entered into an agreement with existing accredited investors to exercise a total of 10,344,000 shares of common stock warrants, expected to generate $1.9 million in cash flow, thereby enhancing its financial strength to support future R&D initiatives.
- New Warrant Issuance: To incentivize existing investors for immediate exercise, the company issued a total of 20,688,000 new warrants with an exercise price of $0.18 per share, which is anticipated to boost investor confidence and encourage shareholder participation.
- Compliance and Registration Statement: The new warrants will become exercisable upon obtaining shareholder approval, and the company plans to file a registration statement with the SEC to ensure compliance for future stock transactions, thereby reducing legal risks and enhancing market transparency.
- Role of Financial Advisor: Maxim Group LLC acted as the financial advisor for this transaction, facilitating the successful exercise of warrants, which underscores the company's professionalism and strategic planning capabilities in capital market operations.
See More
Liminatus Pharma Receives Nasdaq Delisting Notice
- Delisting Notice: Liminatus Pharma received a delisting notice from Nasdaq on May 20, 2026, indicating the company has failed to regain compliance with Nasdaq's continued listing rules, which could lead to termination of its stock trading on Nasdaq.
- Compliance Issues: The company was previously notified of its non-compliance with Nasdaq's market value requirements of $50 million for listed securities and $15 million for publicly held shares, which directly impacts its credibility in the capital markets.
- Appeal Plans: Liminatus Pharma intends to appeal to the relevant panel in an effort to regain its listing status, a move that may influence investor confidence and the company's future financing capabilities.
- Financial Health Concerns: The delisting notice raises market concerns about Liminatus Pharma's financial health, potentially leading to stock price volatility and affecting its competitive position in the biopharmaceutical industry.
See More
Liminatus Pharma Amends Merger Agreement with InnocsAI
- Merger Agreement Restructuring: Liminatus Pharma has amended its merger agreement with InnocsAI, allowing the transaction to close before obtaining stockholder approval, now expected on July 2, 2026, demonstrating the company's commitment to rapid strategic integration.
- Transaction Terms Details: Under the amended terms, InnocsAI equity holders will receive a mix of Liminatus common stock and newly designated non-voting convertible preferred stock, with an implied transaction value of approximately $320 million, reflecting confidence in future growth prospects.
- Equity Structure Arrangement: InnocsAI holders will receive up to 19.99% of Liminatus common shares, with the remainder in non-voting convertible preferred stock that can only convert to common shares upon stockholder approval, adhering to Nasdaq regulations.
- Strategic Significance: Liminatus CEO Chris Kim stated that this merger represents a pivotal step in the company's strategy to diversify its oncology biotech portfolio, as InnocsAI's cell therapy platform complements Liminatus' immuno-oncology programs, creating multiple opportunities for long-term shareholder value.
See More
Liminatus Pharma Amends Merger Agreement with InnocsAI
- Merger Agreement Restructured: Liminatus Pharma has amended its merger agreement with InnocsAI to allow closing before stockholder approval, expected on July 2, 2026, demonstrating the company's commitment to rapid strategic integration.
- Significant Transaction Value: The total implied value of the transaction is approximately $320 million, with InnocsAI equity holders receiving a mix of Liminatus common stock and newly designated non-voting convertible preferred stock, indicating flexibility and innovation in the company's capital structure.
- Strategic Integration Opportunities: Post-merger, Liminatus will expand its oncology pipeline by integrating cell therapy and immunotherapy, which is expected to yield multiple preclinical product candidates and enhance future market competitiveness.
- Shareholder Value Enhancement: The merger is poised to create long-term shareholder value, particularly as the diversified oncology platform is likely to attract more strategic partnerships and licensing opportunities, further solidifying its market position.
See More
Liminatus Pharma Enters Warrant Exercise Agreement
- Financing Agreement: Liminatus Pharma has signed a warrant exercise agreement with existing accredited investors to exercise a total of 10.34 million warrants, expected to generate $1.9 million in cash flow, enhancing its financial flexibility to support R&D initiatives.
- New Warrant Issuance: Concurrently with the exercise of existing warrants, holders were issued new unregistered warrants for a total of 20.688 million shares at an exercise price of $0.18 per share, indicating the company's confidence in future shareholder approval.
- Stock Price Volatility: LIMN's stock has traded between $0.13 and $33.66 over the past year, closing at $0.15 on Wednesday, down 22.21%, reflecting market caution regarding the company's short-term outlook.
- Market Reaction: In pre-market trading, LIMN shares rose 0.20% to $0.15, and despite the overall weak performance, the market's response to the new financing agreement shows a degree of optimism.
See More
Liminatus Pharma Enters Warrant Exercise Agreement
- Financing Progress: Liminatus Pharma has entered into a warrant exercise agreement, expected to generate $1.9 million in gross proceeds, enhancing the company's liquidity to support future R&D initiatives.
- Share Issuance: The agreement involves the exercise of 10.34 million shares of common stock warrants while issuing 20.68 million new unregistered warrants, which may dilute existing shareholders' equity but provides additional capital support for the company.
- Market Reaction: The market reacted positively to the agreement, with investors expressing optimism about the company's future growth potential, which could drive the stock price up in the short term and bolster market confidence.
- Strategic Implications: This financing allows Liminatus Pharma to accelerate its R&D projects, particularly in new drug development, aiming to enhance its competitiveness and market position in the biopharmaceutical industry.
See More
Liminatus Pharma Enters Warrant Exercise Agreement for $1.9 Million
- Warrant Exercise Agreement: Liminatus Pharma has entered into an agreement with existing accredited investors to exercise a total of 10,344,000 shares of common stock warrants, expected to generate $1.9 million in cash flow, thereby enhancing its financial strength to support future R&D initiatives.
- New Warrant Issuance: To incentivize existing investors for immediate exercise, the company issued a total of 20,688,000 new warrants with an exercise price of $0.18 per share, which is anticipated to boost investor confidence and encourage shareholder participation.
- Compliance and Registration Statement: The new warrants will become exercisable upon obtaining shareholder approval, and the company plans to file a registration statement with the SEC to ensure compliance for future stock transactions, thereby reducing legal risks and enhancing market transparency.
- Role of Financial Advisor: Maxim Group LLC acted as the financial advisor for this transaction, facilitating the successful exercise of warrants, which underscores the company's professionalism and strategic planning capabilities in capital market operations.
See More
Liminatus Pharma Receives Nasdaq Delisting Notice
- Delisting Notice: Liminatus Pharma received a delisting notice from Nasdaq on May 20, 2026, indicating the company has failed to regain compliance with Nasdaq's continued listing rules, which could lead to termination of its stock trading on Nasdaq.
- Compliance Issues: The company was previously notified of its non-compliance with Nasdaq's market value requirements of $50 million for listed securities and $15 million for publicly held shares, which directly impacts its credibility in the capital markets.
- Appeal Plans: Liminatus Pharma intends to appeal to the relevant panel in an effort to regain its listing status, a move that may influence investor confidence and the company's future financing capabilities.
- Financial Health Concerns: The delisting notice raises market concerns about Liminatus Pharma's financial health, potentially leading to stock price volatility and affecting its competitive position in the biopharmaceutical industry.
See More
